{"success":true,"data":{"pressRelease":{"id":"42511","rtpr_id":"nACSHk8mja","ticker":"WGS","exchange":"NASDAQ","all_tickers":["WGS"],"title":"Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Reach Out","author":"ACCESSWIRE","published_at":"2026-05-21T15:00:04.762Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May\n21, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential\nclaims on behalf of purchasers of GeneDx Holdings Corp. (\"GeneDx\" or \"the\nCompany\") (NASDAQ:WGS). Investors who purchased GeneDx securities are\nencouraged to obtain additional information and assist the investigation by\nvisiting the firm's site: bgandg.com/WGS.\n(https://bgandg.com/WGS/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=WGS)\n(https://app.accessnewswire.com/imagelibrary/7d197ed1-ad1b-4070-8919-af44fb2b08f4/bronstein-gewirtz-and-grossman-llc.png)\nGeneDx Investigation Details\n\nOn May 4, 2026, after market hours, GeneDx released its first quarter 2026\nfinancial results, revealing earnings per share of -$0.28, and a $57.5 million\nloss from operations. The Company also lowered its 2026 revenue guidance by\napproximately $65 million at the midpoint. GeneDx revealed it had\n\"lower-than-expected blended average reimbursement rate for exome and genome\"\nand \"softer-than-expected performance from [its] noncore business lines\"\nincluding Fabric Genomics. The Company also took a $31.3 million write-down\nrelated to the goodwill and intangible assets of its Fabric Genomics reporting\nunit, \"primarily due to a downward revision of forecasted cash flows driven by\nchanges in commercial strategy and go-to-market execution, and lower revenue\nand profitability expectations.\" Following this news, GeneDx's stock price\ndropped.\n\nWhat's Next for GeneDx Investors?\n\nIf you are aware of any facts relating to this investigation or purchased\nGeneDx securities, you can assist this investigation by visiting the firm's\nsite: bgandg.com/WGS\n(https://bgandg.com/WGS/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=WGS).\nYou can also contact Peretz Bronstein or his client relations manager, Nathan\nMiller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911 (tel:+9175900911)\n\nNo Cost to GeneDx Investors\n\nWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions\non a contingency fee basis. That means we will ask the court to reimburse us\nfor out-of-pocket expenses and attorneys' fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for GeneDx Securities Investigation?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide.\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1164299)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSHk8mja","title":"Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Reach Out","author":"ACCESSWIRE","ticker":"WGS","created":"2026-05-21T15:00:04.762Z","tickers":["WGS"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May\n21, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential\nclaims on behalf of purchasers of GeneDx Holdings Corp. (\"GeneDx\" or \"the\nCompany\") (NASDAQ:WGS). Investors who purchased GeneDx securities are\nencouraged to obtain additional information and assist the investigation by\nvisiting the firm's site: bgandg.com/WGS.\n(https://bgandg.com/WGS/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=WGS)\n(https://app.accessnewswire.com/imagelibrary/7d197ed1-ad1b-4070-8919-af44fb2b08f4/bronstein-gewirtz-and-grossman-llc.png)\nGeneDx Investigation Details\n\nOn May 4, 2026, after market hours, GeneDx released its first quarter 2026\nfinancial results, revealing earnings per share of -$0.28, and a $57.5 million\nloss from operations. The Company also lowered its 2026 revenue guidance by\napproximately $65 million at the midpoint. GeneDx revealed it had\n\"lower-than-expected blended average reimbursement rate for exome and genome\"\nand \"softer-than-expected performance from [its] noncore business lines\"\nincluding Fabric Genomics. The Company also took a $31.3 million write-down\nrelated to the goodwill and intangible assets of its Fabric Genomics reporting\nunit, \"primarily due to a downward revision of forecasted cash flows driven by\nchanges in commercial strategy and go-to-market execution, and lower revenue\nand profitability expectations.\" Following this news, GeneDx's stock price\ndropped.\n\nWhat's Next for GeneDx Investors?\n\nIf you are aware of any facts relating to this investigation or purchased\nGeneDx securities, you can assist this investigation by visiting the firm's\nsite: bgandg.com/WGS\n(https://bgandg.com/WGS/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=WGS).\nYou can also contact Peretz Bronstein or his client relations manager, Nathan\nMiller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911 (tel:+9175900911)\n\nNo Cost to GeneDx Investors\n\nWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions\non a contingency fee basis. That means we will ask the court to reimburse us\nfor out-of-pocket expenses and attorneys' fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for GeneDx Securities Investigation?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide.\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1164299)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-21T15:00:04.777863803Z","server_sent_at_ms":1779375604777},"received_at":"2026-05-21T15:00:04.844Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1164299"},"analysis":{"id":"31947","press_release_id":"42511","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman, LLC initiated an investigation into potential securities claims on behalf of GeneDx Holdings Corp. (WGS) shareholders.\n\nThe firm cites GeneDx's Q1 2026 results, which included an EPS of -$0.28, a $57.5 million operating loss, and a $65 million cut to 2026 revenue guidance.\n\nThe release is a routine solicitation encouraging investors to contact the firm on a contingency basis; it contains no new disclosures from the issuer itself.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"write_down":31300000,"operating_loss":57500000,"guidance_cut_midpoint":65000000}},"quotedText":"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":[],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"GeneDx Holdings Corp.","ticker":"WGS"},{"name":"Fabric Genomics","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"-$0.28","context":"Q1 2026 earnings per share"},{"amount":"$57.5 million","context":"Q1 2026 loss from operations"},{"amount":"$65 million","context":"2026 revenue guidance cut at midpoint"},{"amount":"$31.3 million","context":"write-down of Fabric Genomics goodwill and intangible assets"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bronstein, Gewirtz & Grossman, LLC. No new disclosure from the issuer; no certified class, no settlement. Boilerplate investigation notice."},"tickerRelevance":{"others":[],"primary":"WGS"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bronstein, Gewirtz & Grossman, LLC initiated an investigation into potential securities claims on behalf of GeneDx Holdings Corp. (WGS) shareholders.\n\nThe firm cites GeneDx's Q1 2026 results, which included an EPS of -$0.28, a $57.5 million operating loss, and a $65 million cut to 2026 revenue guidance.\n\nThe release is a routine solicitation encouraging investors to contact the firm on a contingency basis; it contains no new disclosures from the issuer itself.","key_figures":{"customDimensions":{"write_down":31300000,"operating_loss":57500000,"guidance_cut_midpoint":65000000}},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":[],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"GeneDx Holdings Corp.","ticker":"WGS"},{"name":"Fabric Genomics","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"-$0.28","context":"Q1 2026 earnings per share"},{"amount":"$57.5 million","context":"Q1 2026 loss from operations"},{"amount":"$65 million","context":"2026 revenue guidance cut at midpoint"},{"amount":"$31.3 million","context":"write-down of Fabric Genomics goodwill and intangible assets"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-21T15:05:33.426Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":43298,"modelName":"george-droid-qwen-72b"}}